Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs

International Journal of Oncology

Volumn 30, Issue 6, 2007, Pages 1545-1551

  Chuthapisith, Suebwong ^a   Layfield, Robert ^a   Kerr, Ian D ^a   Hughes, Catherine ^a   Eremin, Oleg ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b LINCOLN COUNTY HOSPITAL   (United Kingdom)

Author keywords

Adriamycin resistant MCF 7 breast cancer cells; Breast cancer; P glycoprotein; Paclitaxel resistant MCF 7 breast cancer cells; Proteomics

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BREAST TUMOR; DRUG RESISTANCE; FEMALE; HUMAN; IMAGE PROCESSING; MASS SPECTROMETRY; METABOLISM; PHYSIOLOGY; PROTEOMICS; TUMOR CELL LINE; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 34447259106     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.6.1545     Document Type: Article

References (30)

1. Bear HD, Anderson S, Brown A, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21: 4165-4174, 2003.
2. Smith IC, Heys SD, Hutcheon AW, et al: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20: 1456-1466, 2002.
3. Chollet P, Charrier S, Brain E, et al: Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 33: 862-866, 1997. (Pubitemid 27287036)
4. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483-2493, 1997.
5. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
6. Brown KJ and Fenselau C: Investigation of doxorubicin resistance in MCF-7 breast cancer cells using shot-gun comparative proteomics with proteolytic 18O labeling 3. J Proteome Res 455-462, 2004.
7. Castagna A, Antonioli P, Astner H, et al: A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 4: 3246-3267, 2004.
8. Chen ST, Pan TL, Tsai YC and Huang CM: Proteomics reveals protein profile changes in doxorubicin-treated MCF-7 human breast cancer cells. Cancer Lett 181: 95-107, 2002.
9. Gehrmann M, Fenselau C and Hathout Y: Highly altered protein expression profile in the adriamycin resistant MCF-7 cell line. J Proteome Res 3: 403-409, 2004.
10. Gehrmann M, Hathout Y and Fenselau C: Evaluation of metabolic labeling for comparative proteomics in breast cancer cells. J Proteome Res 3: 1063-1068, 2004. (Pubitemid 39425664)
11. Poland J, Urbani A, Lage H, Schnolzer M and Sinha P: Study of the development of thermoresistance in human pancreatic carcinoma cell lines using proteome analysis. Electrophoresis 25: 173-183, 2004.
12. Sinha P, Poland J, Kohl S, et al: Study of the development of chemoresistance in melanoma cell lines using proteome analysis. Electrophoresis 24: 2386-2404, 2003.
13. Yang YX, Xiao ZQ, Chen ZC, et al: Proteome analysis of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR. Proteomics 6: 2009-2021, 2006.
14. Davies R, Budworth J, Riley J, Snowden R, Gescher A and Gant TW: Regulation of P-glycoprotein 1 and 2 gene expression and protein activity in two MCF-7/Dox cell line subclones. Br J Cancer 73: 307-315, 1996.
15. Wosikowski K, Regis JT, Robey RW, et al: Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Differ 6: 1395-1403, 1995.
16. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
17. Walker J, Martin C and Callaghan R: Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur J Cancer 40: 594-605, 2004.
18. Guo B, Villeneuve DJ, Hembruff SL, et al: Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. Breast Cancer Res Treat 85: 31-51, 2004.
19. Liu Y, Liu H, Han B and Zhang JT: Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res 66: 3248-3255, 2006.
20. Molloy M, Herbert B, Williams K and Gooley A: Extraction of Escherichia coli proteins with organic solvents prior to two-dimensional electrophoresis. Electrophoresis 20: 701-704, 1999.
21. Alli E, Bash-Babula J, Yang JM and Hait WN: Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 62: 6864-6869, 2002.
22. Parekh HK, Deng HB, Choudhary K, Houser SR and Simpkins H: Overexpression of sorcin, a calcium-binding protein, induces a low level of paclitaxel resistance in human ovarian and breast cancer cells. Biochem Pharmacol 63: 1149-1158, 2002.
23. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, et al: Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 11: 8006-8014, 2005.
24. Duan Z, Lamendola DE, Yusuf RZ, Penson RT, Preffer FI and Seiden MV: Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype. Anticancer Res 22: 1933-1941, 2002.
25. Jakob U, Gaestel M, Engel K and Buchner J: Small heat-shock proteins are molecular chaperones. J Biol Chem 268: 1517-1520, 1993.
26. Wang Y, Serfass L, Roy MO, Wong J, Bonneau AM and Georges E: Annexin-I expression modulates drug resistance in tumor cells. Biochem Biophys Res Commun 314: 565-570, 2004.
27. Zhou Y, Xu Y, Tan Y, et al: Sorcin, an important gene associated with multidrug-resistance in human leukemia cells. Leuk Res 30: 469-476, 2006.
28. Tan Y, Li G, Zhao C, et al: Expression of sorcin predicts poor outcome in acute myeloid leukemia. Leuk Res 27: 125-131, 2003. (Pubitemid 36069079)
29. Zhang B, Zhang Y, Dagher MC and Shacter E: Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Cancer Res 65: 6054-6062, 2005.
30. Keshgegian AA and Cnaan A: Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol 104: 42-49, 1995.